Skip to main content

Table 3 Abomasal fluid pharmacokinetic parameters (mean ± SD, n = 4) for flubendazole (FLBZ) and its reduced metabolite (R-FLBZ) obtained after the intraruminal (i.r.) administration of FLBZ (3.8 mg/kg) formulated as a cyclodextrin-based solution (FLBZ-CDs) or a carboximethylcelullose suspension (FLBZ-CMC) to sheep (Experiment 1)

From: Exploring flubendazole formulations for use in sheep. Pharmacokinetic evaluation of a cyclodextrin-based solution

PHARMACOKINETIC PARAMETERS

FLBZ

R-FLBZ

FLBZ-CDs i.r. treatment

FLBZ-CMC i.r. treatment

FLBZ-CDs i.r. treatment

FLBZ-CMC i.r. treatment

Cmax (μg/mL)

0.11 ± 0.01

0.16 ± 0.06

0.43 ± 0.13

0.67 ± 0.40*

Tmax (h)

10.5 ± 3.00

9.75 ± 2.87

12.8 ± 3.77

12.0 ± 0.00

AUC0-t (μg.h/mL)

2.95 ± 0.66

3.63 ± 1.05

12.0 ± 5.01

21.7 ± 15.8

T½el (h)

12.3 ± 5.99

9.83 ± 4.23

16.2 ± 7.54

16.3 ± 5.95

MRT (h)

23.0 ± 8.28

20.4 ± 5.23

30.0 ± 12.1

31.2 ± 8.80

  1. T½abs/for: FLBZ absorption or metabolite formation half life; Cmax: peak plasma concentration; Tmax: time to the Cmax; AUC 0-t : Area under the plasma concentration vs. time curve from 0 to the detection time; T½el: elimination half-life; MRT: mean residence time (obtained by non-compartmental analysis of the data). *Significantly different from the FLBZ-CDs i.r. treated group at P < 0.05.